The development of selective BRAF V600 inhibitors (BRAFi), which specifically target the mutated BRAF protein, and their subsequent combination with MEK inhibitors (MEKi) has substantially improved outcomes in advanced melanoma. Here, MAP2K7 is linked to melanoma.